4//SEC Filing
ALS Invest 1 B.V. 4
Accession 0000899243-22-016853
CIK 0001658551other
Filed
May 4, 8:00 PM ET
Accepted
May 5, 4:46 PM ET
Size
11.4 KB
Accession
0000899243-22-016853
Insider Transaction Report
Form 4
ALS Invest 1 B.V.
10% Owner
Transactions
- Conversion
Common Stock
2022-01-11+1,129,386→ 1,129,386 total - Conversion
Common Stock
2022-01-11+4,826,503→ 5,955,889 total - Conversion
Series A Preferred Stock
2022-01-11−1,129,386→ 0 total→ Common Stock (1,129,386 underlying) - Conversion
Series B Preferred Stock
2022-01-11−4,826,503→ 0 total→ Common Stock (4,826,503 underlying)
Footnotes (2)
- [F1]Upon the closing of the Issuer's initial public offering, all shares of Series A and Series B preferred stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date.
- [F2]The Reporting Person is managed by SUNU Ventures BV. Felix-Andre von Coerper is the sole corporate director of SUNU Ventures BV and has voting and dispositive power with respect to the securities held by the Reporting Person.
Documents
Issuer
Amylyx Pharmaceuticals, Inc.
CIK 0001658551
Entity typeother
IncorporatedNetherlands
Related Parties
1- filerCIK 0001920501
Filing Metadata
- Form type
- 4
- Filed
- May 4, 8:00 PM ET
- Accepted
- May 5, 4:46 PM ET
- Size
- 11.4 KB